Pain and quality of life in patients undergoing radiotherapy for spinal metastatic disease treatment by Valesin Filho, Edgar S et al.
  Universidade de São Paulo
 
2013
 
Pain and quality of life in patients undergoing
radiotherapy for spinal metastatic disease
treatment
 
 
International Archives of Medicine, London, v.6, p.1-8, feb.2013
http://www.producao.usp.br/handle/BDPI/34949
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Escola de Artes, Ciências e Humanidades - EACH Artigos e Materiais de Revistas Científicas - EACH
ORIGINAL RESEARCH Open Access
Pain and quality of life in patients undergoing
radiotherapy for spinal metastatic disease
treatment
Edgar S Valesin Filho1, Luiz Carlos de Abreu2, Guilherme HV Lima1, Daniel IG de Cubero1, Fabrício H Ueno1,
Gustavo SL Figueiredo1, Vitor E Valenti2,3, Carlos Bandeira de Mello Monteiro2,4, Rubens Wajnsztejn2,
Edison N Fujiki1,2, Modesto Rolim Neto2 and Luciano M Rodrigues1,2*
Abstract
Background: Radiotherapy is an important tool in the control of pain in patients with spinal metastatic disease. We
aimed to evaluate pain and of quality of life of patients with spinal metastatic disease undergoing radiotherapy
with supportive treatment.
Methods: The study enrolled 30 patients. From January 2008 to January 2010, patients selection included those
treated with a 20 Gy tumour dose in five fractions. Patients completed the visual analogue scale for pain
assessment and the SF-36 questionnaire for quality of life assessment.
Results: The most frequent primary sites were breast, multiple myeloma, prostate and lymphoma. It was found that
14 spinal metastatic disease patients (46.66%) had restricted involvement of three or fewer vertebrae, while 16
patients (53.33%) had cases involving more than three vertebrae. The data from the visual analogue scale
evaluation of pain showed that the average initial score was 5.7 points, the value 30 days after the end of
radiotherapy was 4.60 points and the average value 6 months after treatment was 4.25 points. Notably, this final
value was 25.43% lower than the value from the initial analysis. With regard to the quality of life evaluation, only
the values for the functional capability and social aspects categories of the questionnaire showed significant
improvement.
Conclusion: Radiotherapy with supportive treatment appears to be an important tool for the treatment of pain in
patients with spinal metastatic disease.
Keywords: Radiotherapy, Neoplasm metastasis, Quality of life
Background
Spinal metastatic disease (SMD) is a relatively common
disease and has received increased attention recently
with the development of diagnostic and therapeutic tools
that increase the life expectancy of these oncology
patients [1,2]. Radiotherapy is an important tool for the
control of pain and local neoplastic progression. Several
studies have demonstrated its efficacy in stabilizing the
progression of pain and in maintaining the ability of the
patient to walk, which are considered import goals of
treatment [3-6].
The majority of tumors found in the spine are meta-
static lesions, and approximately 18,000 new cases are
diagnosed annually in the United States [7]. According
to the literature, more than 10% of patients with cancer
will develop symptomatic secondary spinal disease, and
more than 40 to 70% of those cases will involve several
vertebral levels [8-10].
Historically, radiotherapy has been used in the treat-
ment of SMD and is considered the standard treatment
by many authors [11-13]. Several studies have shown
only negligible benefits from decompressive surgery
(i.e., isolated laminectomy), associated or not with
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radiotherapy, when compared to radiotherapy alone for
the treatment of pain and neurological dysfunction in
patients [14]. The current dogma that dictates surgery
for spinal metastatic disease as the procedure of choice
to save the life of a patient has been established for some
time.
However, previous studies have considered laminec-
tomy inefficient in decompressing and resecting a tumor
mass that is found in the vertebral body in most cases.
Moreover, this procedure can lead to vertebral instability
and deformities as well as the possible neurological
and clinical deterioration of the patient. With recent
advances in surgical techniques and the development of
less invasive procedures, as well as earlier and more
precise diagnosis, surgical approaches have shown
improved outcomes in treating oncology patients,
thereby making surgery a first-line treatment in selected
cases [15].
Radiotherapy is still a fundamental therapeutic option
for neoplasms sensitive to this treatment, such as
lymphomas and multiple myelomas. This option is most
commonly used with patients who have lesions at mul-
tiple levels or where surgery would be contraindicated
by the clinical condition of the patient. There is still
controversy with regard to the benefits of surgery,
radiotherapy, chemotherapy or any combination of these
treatments for different groups of patients [16].
Although previous studies have already investigated
the radiation therapy effects on metastasis [17,18], its
effects on immunological responses are hypothesized to
impair the quality of life. Therefore, we aimed to analyze
the progression of pain and of quality of life in patients
undergoing radiotherapy with supportive treatment to
treat SMD-related pain.
Methods
All patients considered for this study were diagnosed
with SMD between January 2008 and January 2010. A
total of 30 patients undergoing radiotherapy for pain
management and to prevent the local progression of the
tumor were included in the study. Patients that had
previous decompressive or stabilization surgeries in
addition to receiving radiotherapy were excluded.
Clinical outpatient evaluation was performed with the
help of the Clinical Oncology team of the same service.
Questionnaires were administered by the treating ortho-
pedic physician specialized in spinal surgery. Patients en-
rolled in the study provided their informed and written
consent. All procedures were approved by the Ethics
Committee in Research of our University.
Details of other supportive treatments other than sur-
gery and radiation therapy included steroid therapy
(dexamethasone, 4 mg every 6 hours), spinal orthotics
and physiotherapy.
The criteria used for radiotherapy indication were the
following: patients selection included those treated with
20 Gy tumour dose, provided in five fractions, control of
local pain that was not treatable by medication, patients
with lesions in multiple levels, patients with pain and
complete neurological deficits for more than 48 hours
after neoplastic spinal cord compression and tumors
sensitive to radiotherapy in patients without progressive
neurological alteration during treatment. All patients
were sent to the same radiotherapy clinic and underwent
treatment with fractionated doses according to a specific
protocol (20 Gy tumour dose in five fractions).
The questionnaire evaluated the pain in SMD subjects
and its impact on quality of life at three different times:
before radiotherapy, 30 days after the end of the treat-
ment and 6 months after the end of the treatment. The
visual analogue scale (VAS) [19] was used to measure
pain, and the SF-36 questionnaire [20,21] was used to
study possible quality of life variations. The SF-36
consists of 36 items that are grouped into the following
eight areas: functional capacity, physical limitations,
pain, overall health, vitality, social aspects, emotional
limitations and mental health. Results were statistically
evaluated using SPSS software (Statistical Package for
Social Sciences, version 17.0) Statistical Package for
Social Sciences software (SPSS, version 17.0) and were
considered significant for p < 0.05.
Results
Thirty patients were chosen for the study, including 18
women (70%) and 12 men (30%). All patients
participated in the evaluation performed 30 days after
the end of radiotherapy. However, by the 6-month
evaluation, there were 10 deaths, thereby resulting in a
survival rate of 66.66%. The distribution of the primary
sites of neoplasm afflicting these patients is presented in
Figure 1. The patients were aged between 40 and 90 -
years old with an average age of 62.2 years old.
Figure 1 Distribution of the primary sites of metastases.
Valesin Filho et al. International Archives of Medicine 2013, 6:6 Page 2 of 8
http://www.intarchmed.com/content/6/1/6
SMD involving three or fewer vertebrae was found in
14 cases (46.66%), whereas SMD that had disseminated
(i.e., lesions in more than three vertebrae) was found in
16 patients (53.33%). Topography characteristic of
restricted lesions was more frequently found in the
thoracic spine (i.e., 8 cases, or 57.14% of the restricted
lesions), although in 5 cases (35.71%) the lesions oc-
curred in the lumbar spine. In 1 case (7.14%), the lesion
occurred in the cervical spine.
The evaluation of pain according to the visual
analogue scale (VAS) yielded an initial average value of
5.7 points. Thirty days after the end of radiotherapy, this
was found to be 4.6 points on average. Six months after
treatment, the average VAS score was 4.25 points
(Figure 2), which is 25.43% lower than the initial value.
To describe and compare the observational periods
regarding the variable VAS, we applied the Friedman
test. The goal of this analysis was to verify possible
differences among the three time points of observation
(Table 1). Patients that died during the study were not
included in this analysis.
Because we found significant difference between the
three testing time points, we applied the Wilcoxon test,
which was adjusted by a Bonferroni correction, in order
to identify the observational periods that were signifi-
cantly different (Table 2).
We observed the main changes in the VAS values
when the pre-radiotherapy period was paired with the
consecutive follow-up analyses, individually. Nevertheless,
no statistically significant alteration in the VAS scores was
found when the 30-day post radiotherapy and 6-month
post radiotherapy time points were compared.
To complete the quality of life evaluation using the
SF-36 questionnaire, we compared the eight distinct
subject areas across the observation time points. We ap-
plied the Friedman test to verify possible differences
among the three observation time points.
Only in the areas of functional capacity (Figure 3) and
social aspects (Figure 4) we found significant higher
values at pre and 6 months post radiotherapy compared
to 1 month post radiotherapy.
We found significant differences in these areas and we
compared the three periods concomitantly. We applied
the Wilcoxon test, which was adjusted by a Bonferroni
correction in order to identify which observation points
where significantly different (Tables 3 and 4).
The average score for functional capacity 6 months
after radiotherapy was 38.75 points. This value is signifi-
cantly higher than the average value obtained for func-
tional capacity 30 days after the end of radiotherapy, which
was 25 points. Analogously, the values for social aspects
observed at the second and third time points were signifi-
cantly different. Specifically, the average value for this pa-
rameter was 74.38 points 6 months post radiotherapy and
was 50.63 points 30 days after the end of treatment.
We also performed statistical analyses to identify pos-
sible correlations between changes in pain levels and the
SMD being restricted or disseminated, but we did not
observe significant differences in the evolution of pain
levels when comparing these two groups by either the
VAS or SF-36 questionnaires.
Discussion
In this study we conducted a prospective analysis of pain
and quality of life evolution in subjects undergoing
radiotherapy with supportive treatment to treat pain
caused by spinal metastatic disease. We found that
radiotherapy and the related adjuvant treatments signifi-
cantly improved the progression of pain at 30 days and
6 months after its application in the treatment of SMD.
Indication
The literature shows that a definitive cure is not an
expected outcome for patients with SMD. The main goal
of treatment is palliative, and life expectancy is generally
Figure 2 Average pain score according to the VAS.
Table 1 Values of VAS for the analyzed time points
Variables n Average Standard deviation Min Max Median
VAS pre radiotherapy 20 5.7 3.05 0.00 10.00 6.5
VAS 1 month post radiotherapy 20 4.6* 2.52 0.00 10.00 5.00
VAS 6 months post radiotherapy 20 4.25* 3.16 0.00 10.00 4.00
*p=0.002: Different from VAS pre radiotherapy.
Valesin Filho et al. International Archives of Medicine 2013, 6:6 Page 3 of 8
http://www.intarchmed.com/content/6/1/6
short, typically ranging from 4 to 15 months [20,22].
The main symptom of SMD is pain. It is presented as
progressive night pains that are generally localized in
segments of the thoracic spine with concomitant clinical
deterioration. The pathophysiologic mechanisms of
osseous pain secondary to neoplasms are multiple and
become even more complex in the spine. These under-
lying factors include chemical mediators, increases in
intraosseous pressure, microfractures, periosteum en-
largement, pathological fractures and deformities [16,22].
Most patients with SMD and spinal cord compression
syndrome (90%) present pain, while 47% present with
symptomatic neurological alterations [23]. Moreover,
only 11% to 34% of patients with spinal cord compres-
sion syndrome are able to walk at the time of diagnosis
[24].
Our investigation indicates radiotherapy with support-
ive treatment as an efficient therapy. According to the
literature, radiotherapy is indicated as the first-line ther-
apy for SMD patents in the following situations: when
complete neurological deficits are sustained for a period
longer than 24 hours, when highly radiosensitive tumors
(lymphoma, myeloma) are diagnosed, when there is in-
volvement of multiple levels, when there is short life ex-
pectancy (less than 3 months) or when serious co-
morbidities contraindicate surgery [15]. Surgery to treat
SMD is indicated in specific cases, such as neurologically
progressive deficits, pathologic deformities, resistance to
radiotherapy and patients with an oncologic prognosis
that is favorable.
Etiology and topography
Currently, there are three theories regarding the origin
of extradural metastatic vertebral lesions: (1) progression
of local disease, (2) retrograde dissemination via the
spinal avalvular venous plexus of Batson and (3) arterial
embolisms [25-28].
All the patients’ lesions were evaluated by magnetic
resonance in our study and were all demonstrated to be
extradural tumors. Classic studies involving autopsy have
shown that the distribution of extradural metastases is
more common in larger vertebrae. Therefore, the pres-
ence of SMD has been documented in the lumbar, thor-
acic and cervical regions with decreasing frequency
[27,29]. Nevertheless, Papadopoulos et al. [28] showed
that symptomatic lesions are most frequent in the thor-
acic region (70%), whereas the lumbar region represents
approximately 20% cases and the cervical region about
10% [30]. Notably, our results are in agreement with the
literature, whereby patients that presented restricted
lesions (i.e., up to three vertebrae involved) were most
frequently affected in the thoracic region. Overall, this
group comprised 8 cases, or 57.14% of patients. We
hypothesize that the small diameter of the vertebral
canal in relation to the thoracic spinal cord caused this
increase in symptoms [8].
The majority of published studies demonstrated that
the major primary sites for extradural vertebral metasta-
sis are the breast, lung and prostate, as well as lymph-
omas, multiple myelomas and renal cell tumors
[27,29-32]. In our study, we observed a predominance of
breast lesions (30%), followed by lymphomas and mul-
tiple myelomas (40%). Byrne et al. [31] observed that
Table 2 Differences between the VAS values when
comparing the time points analyzed in pairs
Pair of variables p
VAS 1 month post radiotherapy vs. VAS pre radiotherapy 0.010
VAS 6 months post radiotherapy vs. VAS pre radiotherapy 0.009
VAS 6 months post radiotherapy vs. VAS 1 month post
radiotherapy
0.546
(alpha for Bonferroni = 0.016952).
Figure 3 Variation in the area of functional capacity using the SF-36.
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approximately 50% of vertebral metastases originated in
one of the three following primary sites: breast, lung or
prostate [33]. In a recent review, Klimo et al. [32]
suggested that neoplasms originate from the following
sites in order of decreasing frequency: renal tumors,
gastrointestinal tissue, thyroid tissue, sarcomas and ma-
lignancies of lymphoreticular tissue (lymphomas and
multiple myelomas) [34].
It is important to mention that the distribution of pri-
mary sites related to SMD may vary from one institution
to another due to regional epidemiological differences
and the specialty of the services involved. Our institution
is a regional clinic for hematology, which justifies the
greater portion of lymphoma and myeloma cases we
encountered when compared to studies from other
institutions.
Evaluation of SMD pain and quality of life with
radiotherapy with supportive treatment
The literature suggests that the response to radiotherapy
should be characterized in terms of pain relief and
functional status [12,13]. In lesions sensitive only to
radiotherapy, positive results occur in more than 80% of
patients [23,24]. Lower rates of response are observed
with lesions that are less sensitive to irradiation. As
reported by Jacobs and Perrin [19], more than 30% of
patients showed improvement in neurological function
due to epidural decompression and more than 60%
achieved pain relief after radiotherapy [19,24]. Zaikova
et al. [33] conducted a study involving an analysis of
pain response among 355 patients that underwent radio-
therapy for SMD. After 2 months of treatment, a favorable
response (partial or total pain relief) was noted in 37% of
patients, which is a lower percentage than is observed
with osseous metastasis patients in general. Taken to-
gether, these results suggest that the presence of patho-
physiological pain is more complex in nature than the
pain associated with vertebral metastatic disease.
Chow et al. [34] reported strong positive response
rates to radiotherapy in the treatment of osseous metas-
tasis, which ranged from 60 to 90%. Nonetheless, the
lowest rates of successful pain relief were observed in
patients with vertebral lesions in other skeletal topog-
raphies [35,36]. Maranzano et al. administered radiother-
apy to treat SMD in 209 patients. After an average of
49 months, 71% of the patients with pain (98% of the
studies participants) showed relief from this symptom
[13,21,35].
Our investigation recorded the regression of pain with
an outpatient evaluation that was quantified by the VAS
Figure 4 Variation in the area of social aspects using the SF-36.
Table 3 Wilcoxon test to evaluate the area of functional
capacity at different time points
Pairs of variables p
SF-36 functional capacity 1 month post radiotherapy vs. SF-36
functional capacity pre radiotherapy
0.067
SF-36 functional capacity 6 months post radiotherapy vs. SF-36
functional capacity pre radiotherapy
0.690
SF-36 functional capacity 6 months post radiotherapy vs. SF-36
functional capacity 1 month post radiotherapy
0.011
(alpha value for Bonferroni = 0.016952).
Table 4 Wilcoxon test to evaluate the area of social
aspects at different time points
Pairs of variables p
SF-36 social aspects 1 month post radiotherapy vs. SF-36 social
aspects pre radiotherapy
0.196
SF-36 social aspects 6 months post radiotherapy vs. SF-36 social
aspects pre radiotherapy
0.095
SF-36 social aspects 6 months post radiotherapy vs. SF-36 social
aspects 1 month post radiotherapy
0.001
(alpha value for Bonferroni = 0.016952).
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questionnaire. At 6 months after the radiotherapy, the
average score was 25.43% lower than the initial value.
This level of pain control is lower than the responses
found in the literature. It is possible that the reduced
pain control observed in our study was due to the fact
that a higher portion of the patients we treated were
afflicted with the advanced stages of the disease. The fact
that 33% patients died within the 6 months following
treatment illustrates this point.
No significant variations in paired evaluations of the
data from the 30-day and 6-month post radiotherapy
time points were found. On the other hand, there was a
significant improvement in pain relief during the 30 days
following radiotherapy that evolved over the course of
the study.
The analysis of quality of life through the SF-36 ques-
tionnaire did not show significant results at the 6-month
evaluation period. The only exceptions were in the areas
of functional capacity and social aspects, which showed
slight improvements when the 6-month time point was
compared with the 30-day time point.
Analysis of the pain section of the SF-36 questionnaire
did not indicate a significant improvement in pain levels,
as was reported by the VAS questionnaire. This differ-
ence may have been because the latter consisted of an
evaluation guided by the symptoms related to the spine
region that was irradiated, while the evaluation of pain
according to the SF-36 questionnaire was influenced by
symptoms related to the overall clinical deterioration of
the patient.
Analgesic medication was also used as an important
resource to help control pain. Indeed, several studies
have avoided the topic of analgesic usage for the further
relief of pain in studies of radiotherapy due to the com-
plexity of the prospective analysis required [2,36,37].
Nevertheless, we did not remove medication from the
patients to avoid health’s impairment of the patient.
The standard dose for efficacious irradiation in SMD
cases consists of 20 to 30 Gy given over 5 to 10 sessions
at the area of vertebral involvement. However, several
variations of this regimen have been utilized [38,39].
Although we administered the radiotherapy in fractional
doses (20 Gy in five fraction), the majority of studies in the
literature do not show differences in pain relief from verte-
bral metastatic disease when radiotherapy is performed as
a single dose or if it is fractionated [37,39,40].
We did not eport significant toxicity in patients
that underwent radiotherapy in the present study.
Complications from the irradiation of the spine are
generally mild. Esophagitis induced by radiation may
occur in lesions of the superior thoracic region,
while irradiation of the inferior thoracic region and
lumbar superior can cause nausea and vomiting.
These adverse reactions are more common at the
beginning of treatment and are regularly controlled
by medication. In contrast, radiation-induced myel-
opathy is a complication that occurs more com-
monly in the latter during treatment, and although it
is rare, it is extremely serious [37,39,40].
Some points are important to be raised. The support-
ive treatment other than surgery and radiation therapy
included spinal orthotics, dexamethasone and physio-
therapy. Unfortunately, we were not able to exclude
these variables, since the withdrawal of those treatments
would negatively affect the patient’s health. Therefore,
we indicate radiation therapy accompanied with those
supportive treatment as effective. Although there are
specific questionnaire for cancer’s patient, we applied
only the SF-36 questionnaire. However, this question-
naire is well accepted in the literature and it was applied
in this disease [41-43]. Patients selection included those
treated with a 20 Gy tumour dose, provided in five
fractions according to a previous study [44]. This
method was decided in order to avoid a possible influ-
ence of different radiotherapy regimens, i.e. 20 Gy in 5
fractions and 30 Gy in 10 fractions.
Although the use of radiation therapy for bony metas-
tases with or without surgery was presented in previous
studies, some studies still considers it as malefic
regarding the immunological responses [45,46]. There-
fore, our study provided important information to
support this type of treatment. Our findings are relevant
to the literature, since quality of life is a very important
issue to be discussed in order to improve clinical
practice [47-51].
Conclusion
Radiotherapy with supportive treatment resulted in a
significant improvement in the progression of pain levels
at 30 days and 6 months after its application in the treat-
ment of SMD. The quality of life evaluation showed only
significant improvement in functional capacity and social
aspects. Thus, radiotherapy with supportive treatment is
indicated a useful tool for the control of pain in patients
with SMD.
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